Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Enterobacteriaceae, Infection”

375 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 375 results

Not applicableStudy completedNCT04276480
What this trial is testing

Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.

Who this might be right for
Enterobacteriaceae Infections
University Hospital, Bordeaux 9
Early research (Phase 1)Study completedNCT02531685
What this trial is testing

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

Who this might be right for
Gastroenteritis Escherichia Coli
National Institute of Allergy and Infectious Diseases (NIAID) 100
Testing effectiveness (Phase 2)Looking for participantsNCT05791396
What this trial is testing

FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae

Who this might be right for
Enterobacteriaceae InfectionsMulti-antibiotic Resistance
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 36
Early research (Phase 1)Study completedNCT01123941
What this trial is testing

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

Who this might be right for
Typhoid Fever
Novartis 50
Testing effectiveness (Phase 2)Study completedNCT00498654
What this trial is testing

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

Who this might be right for
Typhoid Fever
Avant Immunotherapeutics 180
Large-scale testing (Phase 3)Study completedNCT00742469
What this trial is testing

Rifaximin for Prevention of Travellers' Diarrhea

Who this might be right for
Diarrhea
Bausch Health Americas, Inc. 210
Testing effectiveness (Phase 2)Ended earlyNCT00866242
What this trial is testing

Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb

Who this might be right for
Shigella
University of Maryland, Baltimore 20
Not applicableUnknownNCT05850871
What this trial is testing

Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

Who this might be right for
Carbapenem-Resistant Enterobacteriaceae Infection
Qianfoshan Hospital 427
Very early researchStudy completedNCT04543877
What this trial is testing

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study

Who this might be right for
InflammationVaccineIntestinal Permeability+1 more
USDA, Western Human Nutrition Research Center 60
Not applicableActive Not RecruitingNCT04764500
What this trial is testing

Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli

Who this might be right for
Extended Spectrum Beta Lactamases (ESBL) E. Coli
University Hospital, Basel, Switzerland 39
Early research (Phase 1)Study completedNCT01381744
What this trial is testing

Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers

Who this might be right for
Plague
National Institute of Allergy and Infectious Diseases (NIAID) 48
Not applicableUnknownNCT00894036
What this trial is testing

The Burden and Genetic Variability of Extended-Spectrum ß-Lactamase (ESBL) - Producing Pathogens in Swiss Children

Who this might be right for
Enterobacteriaceae Infections
University Hospital, Geneva 100
Testing effectiveness (Phase 2)Looking for participantsNCT06938867
What this trial is testing

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

Who this might be right for
E Coli InfectionsAllogenic Transplant Patients
SNIPR Biome Aps. 24
Post-approval studies (Phase 4)Looking for participantsNCT07236944
What this trial is testing

Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care

Who this might be right for
Febrile Urinary Tract Infection
Uppsala University 560
Not applicableStudy completedNCT01764490
What this trial is testing

Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study

Who this might be right for
Clinically Significant Bacteremia
JESUS RODRIGUEZ BAÑO 1,344
Post-approval studies (Phase 4)WithdrawnNCT01543347
What this trial is testing

Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae

Who this might be right for
Urinary Tract Infection
Belpharma s.a.
Not applicableUnknownNCT03800147
What this trial is testing

Effects of Nutritional Fat on the Growth of Intestinal E. Coli

Who this might be right for
Escherichia Coli Infections
University of Zurich 40
Not applicableLooking for participantsNCT03465683
What this trial is testing

Transmission of ESBL-producing Enterobacteriaceae

Who this might be right for
Hospital Acquired Infection
University Hospital, Basel, Switzerland 2,000
Not applicableStudy completedNCT02420366
What this trial is testing

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Who this might be right for
Urinary Tract Infection, ComplicatedAcute PyelonephritisHospital Acquired Bacterial Pneumonia+2 more
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) 257
Testing effectiveness (Phase 2)Study completedNCT06523231
What this trial is testing

Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

Who this might be right for
Shigellosis
LimmaTech Biologics AG 110
Load More Results